Local therapy for prostate cancer may includes radical prostatectomy and radiotherapy. Both therapies share a complication of urinary incontinence.  These complications also have a substantial impact on the patient’s quality of life.
Approximately 10% of men who have undergone prostate cancer surgery experience persistent urinary incontinence (UI). Some of these men experience total leakage, while others may only experience stress incontinence – loss of urine with a cough, sneeze or laugh.
Traditionally men with urinary incontinence have had to depend on adult diapers, external catheters, leg bags, medication, and uncomfortable penile clamps. These options may be costly, leak, have odor, and produce extreme discomfort.
While artificial sphincter surgery may offer solution, additional surgery is not always possible or wanted by patients with urinary incontinence.
Jack Pacey, MD FRCS, a medical doctor and vascular surgeon and the Chief Executive Officer of Vancouver, BC, based Pacey MedTech, a privately held medical technology company focusing on incontinence research, has created a new system to control urinary incontinence following prostate cancer.
Combined with the Pacey Cuff Turbo urethral control device, the company’ novels Pacey Cuff Guard, made from durable neoprene, which doesn’t irritate the skin, is odorless, and has a slim ergonomic design to ensure a comfortable and discreet fit within form-fitting underwear, is a reusable and washable incontinence barrier specifically for men who have undergone prostate cancer treatment and regularly experience urinary incontinence.
The device is also moisture absorbent padding catches any excess urinary drops, and is a supplementary device designed to add value to the Pacey Cuff Turbo urethral control device (UCD).
According to review, the Pacey Cuff Turbo UCD is more comfortable than traditional penile clamps as it allows consistent and effective blood flow to the penis. The device is designed for compression of the urethra to minimize UI and eliminating possible blood supply restriction pain and damage to the penis from repeated painful ischemic tissue insults.
 Daugherty M, Chelluri R, Bratslavsky G, Byler T. Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. Int Urol Nephrol. 2017 Oct;49(10):1715-1721. doi: 10.1007/s11255-017-1660-5. Epub 2017 Jul 14. [Pubmed][Article]
Last Editorial Review: April 9, 2019
Featured Image: Male patient having consultation with doctor on men’s health in medical clinic. Courtesy:© 2010 – 2019 Fotolia. Used with permission.
Copyright © 2010 – 2019 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.